Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI)

Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI)

According to the data derived from several national and international registries, including SANI (Severe Asthma Network Italy), and considering the strong impact that frequent or regular use of oral corticosteroid has on quality of life (QoL) of severe asthmatics, as well as on the costs for managin...

Detaylı Bibliyografya
Asıl Yazarlar:	Giorgio Walter Canonica, Francesco Blasi, Pierluigi Paggiaro, Gianenrico Senna, Giovanni Passalacqua, Antonio Spanevello, Stefano Aliberti, Diego Bagnasco, Marco Bonavia, Matteo Bonini, Luisa Brussino, Caterina Bucca, Maria F. Caiaffa, Cecilia Calabrese, Gianna Camiciottoli, Marco Caminati, Giovanna E. Carpagnano, Cristiano Caruso, Stefano Centanni, Maria E. Conte, Angelo G. Corsico, Lorenzo Cosmi, Maria T. Costantino, Nunzio Crimi, Simona D’Alò, Maria D'Amato, Stefano Del Giacco, Alessandro Farsi, Elisabetta Favero, Maria P. Foschino Barbaro, Gabriella Guarnieri, Giuseppe Guida, Manuela Latorre, Salvatore Lo Cicero, Carlo Lombardi, Luigi Macchia, Francesco Mazza, Francesco Menzella, Manlio Milanese, Marcello Montagni, Paolo Montuschi, Eleonora Nucera, Roberta Parente, Vincenzo Patella, Girolamo Pelaia, Laura Pini, Francesca Puggioni, Luisa Ricciardi, Fabio L.M. Ricciardolo, Luca Richeldi, Erminia Ridolo, Giovanni Rolla, Pierachille Santus, Nicola Scichilone, Giuseppe Spadaro, Andrea Vianello, Vittorio Viviano, Mona R. Yacoub, Maria C. Zappa, Enrico Heffler
Materyal Türü:	Makale
Dil:	English
Baskı/Yayın Bilgisi:	Elsevier 2020-10-01
Seri Bilgileri:	World Allergy Organization Journal
Konular:	Severe asthma Biologics Oral corticosteroids Real-life Registr
Online Erişim:	http://www.sciencedirect.com/science/article/pii/S1939455120303677

Benzer Materyaller

Patient and physician perspectives on biological treatment in severe asthma: a Severe Asthma Network Italy survey
Yazar:: Claudia Crimi, ve diğerleri
Baskı/Yayın Bilgisi: (2023-11-01)

Economic impact of a more extensive use of FENO testing on the Italian population with asthma
Yazar:: Carla Rognoni, ve diğerleri
Baskı/Yayın Bilgisi: (2023-06-01)

Biologics in Severe Eosinophilic Asthma: Three-Year Follow-Up in a SANI Single Center
Yazar:: Paolo Solidoro, ve diğerleri
Baskı/Yayın Bilgisi: (2022-01-01)

Critical evaluation of asthma biomarkers in clinical practice
Yazar:: Giuseppe Guida, ve diğerleri
Baskı/Yayın Bilgisi: (2022-10-01)

Nasal polyps impact in severe asthma patients: evidences from the SANI
Yazar:: Giorgio Walter Canonica, ve diğerleri
Baskı/Yayın Bilgisi: (2020-08-01)

Asthma severity: the patient’s point of view
Yazar:: Gabriella Guarnieri, ve diğerleri
Baskı/Yayın Bilgisi: (2024-12-01)

Is Bronchiectasis (BE) Properly Investigated in Patients with Severe Asthma? A Real-Life Report from Eight Italian Centers
Yazar:: Giovanna Elisiana Carpagnano, ve diğerleri
Baskı/Yayın Bilgisi: (2023-10-01)

Profiling severe asthma: Any relevance for age? An analysis from Severe Asthma Network Italy (SANI) cohort
Yazar:: Marco Caminati, MD, ve diğerleri
Baskı/Yayın Bilgisi: (2024-08-01)

Long-Term Efficacy of Mepolizumab at 3 Years in Patients with Severe Asthma: Comparison with Clinical Trials and Super Responders
Yazar:: Diego Bagnasco, ve diğerleri
Baskı/Yayın Bilgisi: (2023-08-01)

Phenotype overlap in the natural history of asthma
Yazar:: Fabio L.M. Ricciardolo, ve diğerleri
Baskı/Yayın Bilgisi: (2023-05-01)

Predictors of reversible airway obstruction with omalizumab in severe asthma: a real-life study
Yazar:: Paolo Solidoro, ve diğerleri
Baskı/Yayın Bilgisi: (2019-04-01)

Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study
Yazar:: Alessandra Vultaggio, ve diğerleri
Baskı/Yayın Bilgisi: (2023-05-01)

Manifesto on the overuse of SABA in the management of asthma: new approaches and new strategies
Yazar:: Giorgio Walter Canonica, ve diğerleri
Baskı/Yayın Bilgisi: (2021-09-01)

Biologics as well as inhaled anti-asthmatic therapy achieve clinical remission: Evidence from the Severe Asthma Network in Italy (SANI)
Yazar:: Giorgio Walter Canonica, MD, ve diğerleri
Baskı/Yayın Bilgisi: (2025-01-01)

Tezepelumab: patient selection and place in therapy in severe asthma
Yazar:: Francesco Menzella, ve diğerleri
Baskı/Yayın Bilgisi: (2024-04-01)

Treatment strategies for asthma: reshaping the concept of asthma management
Yazar:: Alberto Papi, ve diğerleri
Baskı/Yayın Bilgisi: (2020-08-01)

Benralizumab in Patients With Severe Eosinophilic Asthma With and Without Chronic Rhinosinusitis With Nasal Polyps: An ANANKE Study post-hoc Analysis
Yazar:: Maria D'Amato, ve diğerleri
Baskı/Yayın Bilgisi: (2022-05-01)

Omalizumab as add‐on therapy in a patient with severe asthma and OSA
Yazar:: Giulia Scioscia, ve diğerleri
Baskı/Yayın Bilgisi: (2020-03-01)

Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps
Yazar:: Corrado Pelaia, ve diğerleri
Baskı/Yayın Bilgisi: (2023-03-01)

Efficacy of Mepolizumab in patients with previous Omalizumab treatment failure: real life observation
Yazar:: Diego Bagnasco, ve diğerleri
Baskı/Yayın Bilgisi: (2020-08-01)

The evidence on tiotropium bromide in asthma: from the rationale to the bedside
Yazar:: Dejan Radovanovic, ve diğerleri
Baskı/Yayın Bilgisi: (2017-05-01)

Vascular remodeling and TSLP/angiogenin overexpression in severe mixed asthma
Yazar:: Francesca Bertolini, ve diğerleri
Baskı/Yayın Bilgisi: (2025-02-01)

Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab
Yazar:: Erminia Ridolo, ve diğerleri
Baskı/Yayın Bilgisi: (2020-10-01)

Erratum to: The evidence on tiotropium bromide in asthma: from the rationale to the bedside
Yazar:: Dejan Radovanovic, ve diğerleri
Baskı/Yayın Bilgisi: (2017-06-01)

Is it severe asthma or asthma with severe comorbidities?
Yazar:: Brussino L, ve diğerleri
Baskı/Yayın Bilgisi: (2017-11-01)

Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma
Yazar:: Giovanna Elisiana Carpagnano, ve diğerleri
Baskı/Yayın Bilgisi: (2021-03-01)

Positioning tezepelumab for patients with severe asthma: from evidence to unmet needs
Yazar:: Carlo Lombardi, ve diğerleri
Baskı/Yayın Bilgisi: (2024-11-01)

The extracellular matrix of the lung and airway responsiveness in asthma
Yazar:: F.G. Salerno, ve diğerleri
Baskı/Yayın Bilgisi: (2016-01-01)

Very long-term data on patients with severe eosinophilic asthma treated with mepolizumab: a case series
Yazar:: Carlo Lombardi, ve diğerleri
Baskı/Yayın Bilgisi: (2024-07-01)

Alexithymia and asthma: a systematic review
Yazar:: Orlando Silvestro, ve diğerleri
Baskı/Yayın Bilgisi: (2023-08-01)

Interleukin-5 in the Pathophysiology of Severe Asthma
Yazar:: Corrado Pelaia, ve diğerleri
Baskı/Yayın Bilgisi: (2019-12-01)

Severe uncontrolled asthma with bronchiectasis: a pilot study of an emerging phenotype that responds to mepolizumab
Yazar:: Carpagnano GE, ve diğerleri
Baskı/Yayın Bilgisi: (2019-03-01)

Improvement of patient-reported outcomes in severe allergic asthma by omalizumab treatment: the real life observational PROXIMA study
Yazar:: Giorgio Walter Canonica, ve diğerleri
Baskı/Yayın Bilgisi: (2018-11-01)

Introduction of the telemonitoring device Turbo+ in the management of patients suffering from asthma in Italy: a budget impact analysis
Yazar:: Filippo Rumi, ve diğerleri
Baskı/Yayın Bilgisi: (2022-04-01)

Comparison between clinical trials and real-world evidence studies on biologics for severe asthma
Yazar:: Francesco Menzella, ve diğerleri
Baskı/Yayın Bilgisi: (2022-11-01)

Switching from one biologic to benralizumab in patients with severe eosinophilic asthma: An ANANKE study post hoc analysis
Yazar:: Cristiano Caruso, ve diğerleri
Baskı/Yayın Bilgisi: (2022-09-01)

Real-world characteristics of “super-responders” to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis
Yazar:: Andrea Portacci, ve diğerleri
Baskı/Yayın Bilgisi: (2023-10-01)

Eosinophil Cationic Protein Variation in Patients with Asthma and CRSwNP Treated with Dupilumab
Yazar:: Andrea Giovanni Ledda, ve diğerleri
Baskı/Yayın Bilgisi: (2023-09-01)

Dupilumab in the Treatment of Severe Uncontrolled Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) and Comorbid Asthma—A Multidisciplinary Monocentric Real-Life Study
Yazar:: Gian Luca Fadda, ve diğerleri
Baskı/Yayın Bilgisi: (2025-02-01)

Induced sputum is a reproducible method to assess airway inflammation in asthma
Yazar:: Elena Bacci, ve diğerleri
Baskı/Yayın Bilgisi: (2002-01-01)